Final Brand Change Update Reminder $$ Margin Opportunity $$ Flecainide Cap 100 mg & 200 mg
As advised via PHARMAC proposal of 29 January 2019 and the notification of PHARMAC decision of 28 March 2019 there is to be a change in the listing and future sole supply of Flecainide Capsules.
New listing from 1 July 2019
Flecainide-Teva Cap 100 mg 90 Pharmacode 2567113 Schedule price $39.51
Flecainide-Teva Cap 200 mg 90 Pharmacode 2567121 Schedule price $61.06
Incumbent brand Tambocor CR
Tambocor CR Cap 100 mg 30 Pharmacode 234532 Schedule price $38.95
Tambocor CR Cap 200 mg 30 Pharmacode 234540 Schedule price $68.78
HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 December 2019.
Brand switch fee for Community Pharmacy will apply from 1 December 2019 to 28 February 2020.
In association with Radiant Health Limited ProPharma / PWR will accept full packs of Tambocor CR Cap 100 mg & 200 mg 30 for credit.
Click here to access the analysis showing the significant advantage of continuing with the incumbent Tambocor for as long as possible. Radiant Health have improved your profitability and ensured there is no risk to your business by providing SOR as described below.
Radiant Health Limited are providing an additional 10% discount on the reimbursement price effective 1 July 2019 on a Sale or Return basis, making it more profitable for you to maintain dispensing Tambocor until 30 November 2019.
All remaining stock (full packs only) held after 30 November 2019 can be returned for a full credit, but must be returned no later than 14 December 2019 allowing us to return all stock to Radiant Health Limited for a full and final credit no later than 31 December 2019. (No credits will be processed after the 14th December 2019- no exceptions)
We would recommend you continue to purchase and dispense the incumbent and we will implement automatic replacement as existing stocks are exhausted or 1 December 2019 (whichever comes first)
From 1 July 2019 community pharmacies dispensing Flecainide CR will need to support patients changing to the new brand (where applicable) and manage stock during the transition.
ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 December 2019 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.
Together we can make this a seamless and painless transition.
We thank you in anticipation of your ongoing support.